Novocure Gmbh

Einav Zeevi

Moshe Giladi

Yoram Palti

Zeev Bomzon

Tali Voloshin-Sela

Eilon Kirson

Shiri Davidi

Cornelia Wenger

Uri Weinberg

Adrian Kinzel

Karnit Gotlib

Rosa S Schnaiderman

Cancer treatment using TTFields (Tumor Treating Fields) can be customized to each individual subject by obtaining cancer cells from the subject, determining an electrical characteristic (e.g., dielectrophoretic forces, cell membrane capacitance, etc.) of the cancer cells, determining a frequency for the TTFields based on the determined electrical characteristic, and treating the cancer by applying TTFields to the subject at the determined frequency. In addition, cancer treatment can be planned for each individual subject by obtaining cancer cells from the subject, determining an electrical characteristic of the cancer cells, predicting whether TTFields would be effective to treat the cancer based on the determined electrical characteristic, and treating the subject by applying TTFields if the prediction indicates that TTFields would be effective.

Determining a frequency for TTFields treatment based on an electrical characteristic of targeted cancer cells

Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.

Methods and compositions for treating tumors with TTFields and sorafenib

Growing community of inventors

Zichron Yaakov, Israel

Einav Zeevi